You are here
Genmab’s 2018 Capital Markets Day
- Genmab’s 2018 Capital Markets Day taking place today, will also be webcast live
- Number of Genmab internal speakers, including Executive Management
- Topics include updates on products, next generation technologies, the pipeline and business progress
- Announcement innovative HexElect™ antibody platform
Copenhagen, Denmark; September 26, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) will hold a Capital Markets Day for analysts and investors today from 2:00 PM CEST to 5:00 PM CEST. The event will take place in Genmab’s R&D Center in Utrecht, the Netherlands and will also be webcast live and archived on the company’s website. A number of Genmab speakers, including Executive Management, will give presentations on Genmab’s business including:
- Progress on 2018 milestones
- Proprietary technologies
- Announcement HexElect antibody platform
- Building world class clinical development team and translational research unit
- Pre-clinical pipeline update
- Clinical pipeline update
- Commercial next steps for tisotumab vedotin
During the event Genmab will introduce its new proprietary technology - the HexElect antibody platform. This unique technology combines two HexaBody molecules designed to effectively and selectively hit only those cells that express both targets. The HexElect platform maximizes potency while minimizing potential toxicity.
“Our cutting edge science and passion for innovation are at Genmab’s core. We are very excited to provide an update on the robust progress with our world-class innovative pipeline, as well as introducing HexElect, our novel next generation antibody therapeutics platform. This technology has been inspired by Genmab’s HexaBody technology and unlocks potency by making the action of two HexaBody molecules dependent on binding to two different targets on the same cell. The technology has the potential to create leap-frog cancer therapeutic products with unprecedented efficacy and selectivity,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
To view the webcast, visit https://edge.media-server.com/m6/p/nqrqso5c. Webcast viewers may submit questions during the Q&A portion of the live webcast via the webcast player. An archive of the webcast will be available on Genmab’s website. The meeting will be conducted in English.
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications and other blood cancers. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect™ platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication
T: +45 33 44 77 20; M: +45 25 12 62 60; E: firstname.lastname@example.org
This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.
Media Release no. 08
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Kalvebod Brygge 43
1560 Copenhagen V